For now, early detection of breast and prostate cancer means mammograms and PSAs, but a more tailored approach is on the horizon
Sept. 29, 2017
| By Diane Mapes / Fred Hutch News Service
For now, screening for breast and prostate cancer involves mammograms, MRIs and PSAs, the best evidence-based tools available at this moment in time. But it won’t be this way forever. Fred Hutch researchers weigh in on where we are on the path to precision prevention.
New research writes latest chapter in one drug's story
June 27, 2017
| by Susan Keown / Fred Hutch News Service
The leukemia drug gemtuzumab ozogamicin (Mylotarg) was pulled from the market seven years after initial approval. Now, new evidence may be bringing it back to life to treat a specific group of patients.
‘Functional genomics’ method aims to marry three powerful techniques to speed personalized cancer treatments to patients
March 31, 2017
| By Rachel Tompa / Fred Hutch News Service
Dr. Christopher Kemp is confident that the answer to personalized cancer treatment is written in the molecules inside each patient’s tumor, we just need to figure out how to separate the wheat from the chaff.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.